Amphastar Pharmaceuticals Inc(AMPH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 13.8 | EPS (ttm) | 1.71 | Insider Own | 26.39% | Shs Outstand | 42.5M | Perf Week | -0.84% |
| Market Cap | 1.00B | Forward P/E | 7.4 | EPS next Y | 7.09% | Insider Trans | -0.17% | Shs Float | 31.3M | Perf Month | 15.28% |
| Enterprise Value | 1.40B | PEG | 5.52 | EPS next Q | 0.86 | Inst Own | 68.23% | Short Float | 17.2% | Perf Quarter | 16.02% |
| Income | 0.08B | P/S | 1.37 | EPS this Y | -8.59% | Inst Trans | -9.79% | Short Ratio | 11.26 | Perf Half Y | 25.41% |
| Sales | 0.73B | P/B | 1.3 | EPS next 5Y | 1.34% | ROA | 4.68% | Short Interest | 5.39M | Perf YTD | -12.1% |
| Book/sh | 18.06 | P/C | 3.42 | EPS past 3/5Y | 5.29% 134.65% | ROE | 10.3% | 52W High | -20.26% ($29.52) | Perf Year | -17.11% |
| Cash/sh | 6.88 | P/FCF | 6.55 | Sales past 3/5Y | 12.99% 15.53% | ROIC | 5.44% | 52W Low | 41.42% ($16.65) | Perf 3Y | -52.93% |
| Dividend Est. | - | EV/EBITDA | 7.81 | EPS Y/Y TTM | -38.09% | Gross Margin | 45.61% | Volatility(W/M) | 3.23% 3.09% | Perf 5Y | 32.02% |
| Dividend TTM | - | EV/Sales | 1.91 | Sales Y/Y TTM | 1.02% | Oper. Margin | 15.66% | ATR (14) | 0.76 | Perf 10Y | 29.7% |
| Dividend Ex-Date | - | Quick Ratio | 1.71 | EPS Q/Q | 6.44% | Profit Margin | 10.76% | RSI (14) | 67.56 | Recom | 3.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.4 | Sales Q/Q | 5.44% | SMA20 | 6.16% ($22.17) | Beta | 0.91 | Target Price | $22.5 |
| Payout | - | Debt/Eq | 0.9 | Earnings | 2026/8/6 | SMA50 | 13.76% ($20.69) | Rel Volume | 1.04 | Prev Close | $23.04 |
| Employees | 1976 | LT Debt/Eq | 0.88 | EPS/Sales Surpr. | 46.75% 2.21% | SMA200 | 4.7% ($22.48) | Avg Volume(3M) | 0.48M | Price | $23.54 |
| IPO | 2014/6/25 | Option/Short | Yes/Yes | Trades | 7141 | Volume | 495,998 | Change | 2.17% |
Company
AMPH is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Ampastar Pharmaceutical Industries is a U.S. specialty and generic pharmaceutical company focused on injectable and inhaled products. It trades under the ticker AMPH. The company directly develops and manufactures products including the glucagon nasal powder BAQSIMI, the generic inhaler Primatene Mist, and injectable medications for emergency and chronic conditions such as epinephrine and lidocaine. Through a vertically integrated production system that spans from raw materials to finished products, it secures both quality and cost competitiveness at the same time.
Over the past 1 year, roughly in the middle
20% below its 1-year high.
AMPH makes money exceptionally well
15.66% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -8.6% this year.
Tap to view numbers
The stock looks undervalued
Trading at 13.8 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Would have changed by -52.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 68.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PJP 0.02%
XPH 0.01%
ACVT 0.01%
PILL 0.01%
SIXS 0.01%It ranks #4 in the industry
Based on market cap of $1B.
AMPH $1B PER 13.8
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is AMPH?
AMPH belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AMPH?
The market cap of AMPH is approximately $1.0B, ranking 2,652 within its sector.
What is the P/E ratio of AMPH?
AMPH has a P/E ratio of approximately 13.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for AMPH?
AMPH has recorded a 52-week high of $29.52 and a low of $16.65.
